Entrada Therapeutics
TRDA
117 hedge funds and large institutions have $179M invested in Entrada Therapeutics in 2025 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 49 increasing their positions, 28 reducing their positions, and 16 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 28
63% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 16
37% more call options, than puts
Call options by funds: $111K | Put options by funds: $81K
9% more funds holding
Funds holding: 107 → 117 (+10)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
3.09% less ownership
Funds ownership: 82.53% → 79.44% (-3.1%)
15% less capital invested
Capital invested by funds: $210M → $179M (-$31.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$3.9M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.48M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.38M |
| 4 |
Renaissance Technologies
New York
|
+$1.26M |
| 5 |
Jane Street
New York
|
+$1.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12.9M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$10.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.72M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$685K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$622K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HCA
126
Harbor Capital Advisors
Chicago,
Illinois
| – | -$103K | -15,277 | Closed |
|
127
Squarepoint
New York
| – | -$75.3K | -11,208 | Closed |
|
|
SOW
128
State of Wyoming
Cheyenne,
Wyoming
| – | -$50.9K | -7,575 | Closed |
|
129
US Bancorp
Minneapolis,
Minnesota
| – | -$19.3K | -2,868 | Closed |
|
130
Lazard Asset Management
New York
| – | -$8K | -1,256 | Closed |
|
|
BIG
131
Brooklyn Investment Group
Brooklyn,
New York
| – | -$2.64K | -393 | Closed |
|
|
AF
132
Allworth Financial
Folsom,
California
| – | -$417 | -62 | Closed |
|
|
S
133
SignatureFD
Atlanta,
Georgia
| – | -$356 | -53 | Closed |
|
TRDA Hedge Fund Activity: Q3 2025 in Review
117 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q3 2025, worth a combined $179M — down 15% from $210M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new TRDA positions and 16 closed out — a net gain of 10 holders — while 49 added to existing stakes and 28 trimmed.
The largest buyer was Millennium Management, adding an estimated $3.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $12.9M.
- 117 institutional investors held Entrada Therapeutics (TRDA) as of Q3 2025, up from 107 in Q2 2025.
- Funds reported $179M of Entrada Therapeutics stock for Q3 2025, down 15% quarter-over-quarter.
- 26 funds opened new Entrada Therapeutics positions in Q3 2025 and 16 closed out, a net change of +10 holders.
- The largest Entrada Therapeutics buyer in Q3 2025 was Millennium Management, an estimated $3.9M added.
- The largest Entrada Therapeutics seller in Q3 2025 was T. Rowe Price Associates, an estimated $12.9M sold.
Based on aggregated 13F filings for Q3 2025.